A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Sep 2021 Results (n=48) evaluating the efficacy and safety of palbociclib in patients with recurrent or refractory advanced Thymic Epithelial Tumor, presented at the 2021 World Conference on Lung Cancer
08 Jun 2021 Status changed to recruiting, according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
08 Jun 2021 Results (n=48) presented at the 57th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com